3 results
The primary objective of the study is to demonstrate a reduction in intravascular hemolysis by REGN3918 over 26 weeks of treatment in patientswith active PNH who are treatment-naive to complement inhibitor therapy or have not recently received…
The primary objective of the study is to evaluate the long-term safety, tolerability, and effect on intravascular hemolysis (ie, proportion ofpatients achieving lactate dehydrogenase (LDH) * 1.5× upper limit of normal (ULN) over 26 weeks) of…
The primary objective is the degree of IOP lowering after trabeculectomy with adjuvant Ologen® implantation, in comparison to trabeculectomy with mitomycin-C. Secondary objectives are peroperative and postoperative complications, and postoperative…